December 3,Lexington, Massachusetts, Keros Therapeutics (NASDAQ: KROS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat disorders related to the transforming growth factor-β (“TGF-β") protein family dysfunction signaling-related diseases, announced an exclusive global development and commercial license agreement with Takeda to advance Elritecept (KER-050). Elritercept is currently undergoing two Phase 2 clinical trials; one for patients with very low, low, or intermediate-risk myelodysplastic syndrome (“MDS”), and one for patients with myelofibrosis (“MF”). EvaluationElriterceptThe Phase 3 RENEW clinical trial in transfusion-dependent anemic adult patients with very low, low, or intermediate-risk MDS will soon begin recruitment.According to the terms of the agreement, Takeda will receive an exclusive license to further develop, manufacture, and commercialize elritecept globally outside of mainland China, Hong Kong, and Macao. Takeda will be responsible for all development, manufacturing, and commercialization from the effective date of the agreement. According to the terms of the agreement, Keros will receive$200 million in upfront cash, and is eligible to receive development, regulatory and commercial milestones,Potential value exceeds $1.1 billionKeros will also be eligible for tiered royalties on net sales.
December 13, 2021,Hansoh PharmaTakeda and Keros Therapeutics announced an exclusive licensing agreement for the development, manufacturing, and commercialization of Keros' lead drug, KER-050, in mainland China, Hong Kong, and Macao.Hansoh Pharma Obtains Exclusive Rights for the Development, Manufacturing, and Commercialization of KER-050 in Mainland China, Hong Kong, and Macao. Keros Therapeutics will receive a $20 million upfront payment and is eligible for up to $170.5 million in development and commercial milestone payments, as well as tiered royalties on net sales of the product.Fee.
KER-050 is an "engineered ligand trap,"Composed of the ligand-binding region of a modified TGF-β receptor (i.e., activin receptor type IIA) fused with the Fc region of a human antibody. KER-050 is being developed by Keros Therapeutics for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes (MDS) and myelofibrosis.
Jasbir S. Seehra, Ph.D., Chairman and Chief Executive Officer of Keros Therapeutics, Inc., stated:"We are pleased to announce this agreement with Takeda, a leader in the field of hematologic oncology treatment. We believe this global license further solidifies Keros Therapeutics' position as a leader in understanding the role of TGF-β family proteins and the broad potential of this biological pathway."Chris Rovaldi, President and Chief Operating Officer of Keros Therapeutics, Inc., said:"We believe Takeda is an ideal partner to maximize the potential of elritercept's differentiated profile and build upon the significant progress our team has achieved with elritercept. We anticipate that the net proceeds from the upfront payment will enable us to extend our operational runway into the fourth quarter of 2028, thereby supporting the continued development of cibotercept (KER-012) and KER-065, both of which are wholly-owned assets with near-term clinical updates."P.K. Morrow, Head of Takeda's Oncology Therapeutics Unit, stated:"We are delighted to collaborate with Keros, an exceptional team with outstanding expertise in TGF-β biology. Based on the promising results demonstrated clinically so far, we look forward to continuing to explore its potential and having the opportunity to make it available to patients with hematological disorders. This agreement aligns with our goal of advancing treatments that could transform the treatment paradigm for underserved patient populations."Follow the official account below to see the world!
